Table II.
Clinical Characteristics
| NCI (%) | MGH (%) | Total (%) | |
|---|---|---|---|
| Total patients accrued | 46 (75) | 16 (25) | 62 (100) |
| # evaluable for response | 45 | 16 | 61 |
| # evaluable for toxicity | 46 | 16 | 62 |
| Median age (yrs: range) | 50 (43-69) | 55 (40-69) | 53 (40-69) |
| Stage on study: | |||
| IIIA | 0 | 1 | 1 (1) |
| IIIB | 2 | 1 | 3 (5) |
| IIIC | 23 | 9 | 32 (52) |
| IV* | 21 | 5 | 26 (42) |
| Histology | |||
| Papillary serous | 24 | 13 | 37 (59) |
| Endometrioid/Transitional | 10 | 0 | 10 (16) |
| Undifferentiated | 4 | 0 | 4 (7) |
| Clear Cell | 2 | 1 | 3 (5) |
| Primary peritoneal | 6 | 2 | 8 (13) |
| Tumor Grade | |||
| I | 0 | 1 | 1 (1) |
| II | 9 | 2 | 11 (18) |
| III | 37 | 12 | 49 (79) |
| Sites of Disease | |||
| Liver | 13 | 6 | 19 (31) |
| Spleen | 3 | 1 | 4 (6) |
| Lung/chest parenchymal | 2 | 3 | 5 (8) |
| Mesenteric/omental | 22 | 6 | 28 (45) |
| Retroperitoneal LN | 17 | 2 | 19 (31) |
| Pelvis | 27 | 8 | 35 (56) |
| Pleural effusion | 18 | 4 | 22 (35) |
| Ascites | 21 | 3 | 24 (39) |
*
multiple sites within one organ were counted once.